SpyGlass Pharma (SGP) Jefferies Global Healthcare Conference 2026 summary

Strategic vision and product overview

• Focused on addressing cataracts and glaucoma by combining intraocular lens implantation with multi-year drug elution in a single procedure, aiming to simplify treatment and improve outcomes.

• BIM-IOL system uses bimatoprost, a potent prostaglandin analog, for intraocular pressure (IOP) reduction, chosen for its compatibility and efficacy in the drug delivery system.

• Targets approximately 1 million annual U.S. procedures where patients have both cataracts and glaucoma, with a planned commercial launch in 2029.

• Phase III registration trials are ongoing, with a three-year drug elution profile as the initial commercial product.

• Platform technology is adaptable for other ophthalmic indications and molecules, with potential for future pipeline expansion.

Clinical data and efficacy

• Phase I/II and first-in-human studies show 34–37% mean IOP reduction at 12 months to three years, outperforming standard eye drops.

• High patient retention without need for additional therapy: 95% at three years in FIH, 98% at 12 months in phase II.

• Product avoids compliance issues seen with eye drops, offering consistent, long-term drug delivery.

• Phase III data expected late 2027, with NDA submission planned for first half of 2028 based on three-month data.

Market differentiation and commercial strategy

• Procedure integrates seamlessly into standard cataract surgery, requiring no new skills or tools for most surgeons.

• Addresses a broader surgeon pool compared to competitors, as all cataract surgeons can perform the procedure.

• Additional professional fee confirmed via a new Category III CPT code, with further reimbursement through a J-code for the drug component.

• Pricing expected to be competitive, with a floor around $14,000 for three years of therapy, aligning with existing products.

• Pre-launch efforts focus on building reimbursement confidence and operational systems to ensure smooth adoption.